Novo Submits High-Dose Sema to EMA; Esperion Generic Bempedoic Acid Settlement; Allurion Files Gastric Balloon to FDA; Arrowhead Initiates Ph3 Zodasiran Study
Here is a brief preview of this blast: A series of cardiometabolic-related news items has been observed from Novo Nordisk, Esperion, Allurion Technologies, and Arrowhead Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.